Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Dec;11(12):2128-36.
doi: 10.1111/jth.12433.

Epitope mapping of inhibitory antibodies targeting the C2 domain of coagulation factor VIII by hydrogen-deuterium exchange mass spectrometry

A M Sevy  1 , J F Healey, W Deng, P C Spiegel, S L Meeks, R Li
Affiliations

Epitope mapping of inhibitory antibodies targeting the C2 domain of coagulation factor VIII by hydrogen-deuterium exchange mass spectrometry

A M Sevy et al. J Thromb Haemost. 2013 Dec.

Abstract

Background: The development of anti-factor VIII antibodies (inhibitors) is a significant complication in the management of patients with hemophilia A, leading to significant increases in morbidity and treatment cost. Using a panel of mAbs against different epitopes on FVIII, we have recently shown that epitope specificity, inhibitor kinetics and time to maximum inhibition are more important than inhibitor titer in predicting responses to FVIII and the combination of FVIII and recombinant FVIIa. In particular, a subset of high-titer inhibitors responded to high-dose FVIII, which would not be predicted on the basis of their inhibitor titer alone. Thus, the ability to quickly map the epitope spectrum of patient plasma with a clinically feasible assay may fundamentally change how clinicians approach the treatment of high-titer inhibitor patients.

Objectives: To map the epitopes of anti-FVIII mAbs, three of which are classic inhibitors and one of which is a non-classic inhibitor, by the use of hydrogen-deuterium exchange coupled with mass spectrometry (HDX-MS).

Methods: The binding epitopes of four mAbs targeting the FVIII C2 domain were mapped with HDX-MS.

Results: The epitopes determined with HDX-MS are consistent with those obtained earlier through structural characterization and antibody competition assays. In addition, classic and non-classic inhibitor epitopes could be distinguished by the use of a limited subset of C2 domain-derived peptic fragments.

Conclusion: Our results demonstrate the effectiveness and robustness of the HDX-MS method for epitope mapping, and suggest a potential role of rapid mapping of FVIII inhibitor epitopes in facilitating individualized treatment of inhibitor patients.

Keywords: antigen-antibody complex; epitope mapping; factor VIII; hemophilia A; hydrogen deuterium exchange measurement.

PubMed Disclaimer

Conflict of interest statement

Disclosure of Conflicts of Interest: The authors state that they have no conflict of interest.

Figures

Figure 1
Figure 1
Ribbon diagram showing the structure of fVIII C2 domain (green) in complex with BO2C11 (purple). The primary binding sites around residues 2199 and 2251 are labeled. So is the position of residue 2227.
Figure 2
Figure 2
Sequence coverage of peptides generated by pepsin digestion of the recombinant C2 domain.
Figure 3
Figure 3
HDX profiles of five C2-derived peptides in the absence (□) and presence of indicated inhibitors. Deuterium incorporation varies between classical inhibitors (BO2C11, I109, 3E6) and non-classical inhibitor (G99), implying a distinct binding epitope.
Figure 4
Figure 4
Deuterium incorporation of C2-derived peptides. Deuterium incorporation values overlaid onto (A) the C2 domain primary sequence and (B) its structure. They are colored based on deuterium incorporation per residue (D/res).
Figure 5
Figure 5
HDX protection of the C2 domain by BO2C11 binding. Measured protective indices were overlaid onto (A) the C2 domain primary sequence and (B) its structure. They are colored based on the protective index, ranging from low (yellow) to high protection (red).
Figure 6
Figure 6
Comparison of HDX protection conferred by classical (A-C) and non-classical (D) inhibitors. Structures are colored according to protective indices with red representing stronger protection. Differences in protection pattern are most evident on the Met2199/Phe2200 loop.
See this image and copyright information in PMC

References

    1. Scharrer I, Bray GL, Neutzling O. Incidence of inhibitors in haemophilia A patients--a review of recent studies of recombinant and plasma-derived factor VIII concentrates. Haemophilia. 1999;5:145–154. - PubMed
    1. Hoots WK. The future of plasma-derived clotting factor concentrates. Haemophilia. 2001;7(Suppl 1):4–9. - PubMed
    1. Bray GL, Gomperts ED, Courter S, Gruppo R, Gordon EM, Manco-Johnson M, Shapiro A, Scheibel E, White G, 3rd, Lee M. A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group. Blood. 1994;83:2428–2435. - PubMed
    1. Lusher JM, Lee CA, Kessler CM, Bedrosian CL. The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A. Haemophilia. 2003;9:38–49. - PubMed
    1. Scandella D, Gilbert GE, Shima M, Nakai H, Eagleson C, Felch M, Prescott R, Rajalakshmi KJ, Hoyer LW, Saenko E. Some factor VIII inhibitor antibodies recognize a common epitope corresponding to C2 domain amino acids 2248 through 2312, which overlap a phospholipid-binding site. Blood. 1995;86:1811–1819. - PubMed

Publication types